Molecular Data market cap is $188.7 m, and annual revenue was ¥9.05 b in FY 2018

Molecular Data Revenue growth (FY, 2017 - FY, 2018), %115%

Molecular Data Gross profit (FY, 2018)80.2 M

Molecular Data Gross profit margin (FY, 2018), %0.9%

Molecular Data Net income (FY, 2018)-254.6 M

Molecular Data EBIT (FY, 2018)-235.8 M

Molecular Data Cash, 30-Sept-201936.9 M

Molecular Data EV168.4 M

Molecular Data revenue was ¥9.05 b in FY, 2018 which is a 115.5% year over year increase from the previous period.

Molecular Data revenue breakdown by business segment: 99.9% from Chemical Trading - Direct Sales Model and 0.1% from Other

CNY | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Revenue | 3.2b | 4.2b | 9.1b |

| 31% | 115% | |

## Cost of goods sold | 3.2b | 4.2b | 9.0b |

## Gross profit | 26.1m | 50.2m | 80.2m |

| 1% | 1% | 1% |

## Sales and marketing expense | 59.2m | 65.0m | 103.3m |

## R&D expense | 20.1m | 18.6m | 36.9m |

## General and administrative expense | 41.8m | 41.7m | 173.9m |

## Operating expense total | 131.9m | 141.4m | 316.0m |

## EBIT | (105.8m) | (91.2m) | (235.8m) |

| (3%) | (2%) | (3%) |

## Interest expense | 8.4m | 16.8m | 19.0m |

## Pre tax profit | (113.9m) | (107.8m) | (254.6m) |

## Net Income | (113.9m) | (107.8m) | (254.6m) |

CNY | FY, 2017 | FY, 2018 |
---|---|---|

## Cash | 38.5m | 6.5m |

## Accounts Receivable | 53.9m | 40.7m |

## Prepaid Expenses | 1.1m | 1.7m |

## Inventories | 19.2m | 7.3m |

## Current Assets | 376.5m | 367.7m |

## PP&E | 2.7m | 1.8m |

## Total Assets | 381.1m | 371.6m |

## Accounts Payable | 67.0m | 49.3m |

## Short-term debt | 138.6m | 82.0k |

## Current Liabilities | 299.9m | 255.4m |

## Non-Current Liabilities | 75.4m | 177.8m |

## Total Debt | 138.6m | 82.0k |

## Total Liabilities | 375.2m | 433.2m |

## Common Stock | 98.0k | 98.0k |

## Additional Paid-in Capital | 311.5m | 498.6m |

## Retained Earnings | (305.7m) | (560.3m) |

## Total Equity | 5.9m | (61.6m) |

## Debt to Equity Ratio | 23.5 x | 0 x |

## Debt to Assets Ratio | 0.4 x | 0 x |

## Financial Leverage | 64.6 x | -6 x |

CNY | Q3, 2019 |
---|---|

## Cash | 36.9m |

## Accounts Receivable | 26.8m |

## Prepaid Expenses | 243.0k |

## Inventories | 3.9m |

## Current Assets | 375.0m |

## PP&E | 1.2m |

## Total Assets | 381.0m |

## Accounts Payable | 155.2m |

## Short-term debt | 16.3m |

## Current Liabilities | 374.1m |

## Long-term debt | 273.0k |

## Non-Current Liabilities | 171.0m |

## Total Debt | 16.6m |

## Total Liabilities | 545.1m |

## Common Stock | 98.0k |

## Additional Paid-in Capital | 529.4m |

## Retained Earnings | (693.6m) |

## Total Equity | (164.1m) |

## Financial Leverage | -2.3 x |

CNY | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Net Income | (113.9m) | (107.8m) | (254.6m) |

## Depreciation and Amortization | 978.0k | 1.5m | 2.4m |

## Accounts Receivable | (44.7m) | 15.2m | 13.4m |

## Inventories | (14.8m) | (3.2m) | 11.9m |

## Accounts Payable | 33.1m | (26.5m) | 14.0m |

## Cash From Operating Activities | (145.6m) | (186.7m) | (134.6m) |

## Purchases of PP&E | (2.6m) | (537.0k) | (484.0k) |

## Cash From Investing Activities | (2.6m) | (4.0m) | (2.2m) |

## Long-term Borrowings | (633.4m) | (984.5m) | (833.2m) |

## Cash From Financing Activities | 173.3m | 262.8m | 37.3m |

## Net Change in Cash | 25.1m | 72.2m | (99.5m) |

## Interest Paid | (8.5m) | (17.0m) | (19.4m) |

CNY | Q3, 2018 | Q3, 2019 |
---|---|---|

## Net Income | (88.0m) | (133.2m) |

## Depreciation and Amortization | 1.3m | 2.4m |

## Accounts Receivable | 2.7m | 11.4m |

## Inventories | 10.6m | 3.3m |

## Accounts Payable | 10.2m | 65.6m |

## Cash From Operating Activities | (53.4m) | (33.4m) |

## Purchases of PP&E | (298.0k) | (730.0k) |

## Cash From Investing Activities | (1.3m) | (1.7m) |

## Long-term Borrowings | (748.7m) | |

## Cash From Financing Activities | 21.2m | 104.5m |

## Net Change in Cash | (33.6m) | 69.4m |

## Interest Paid | (15.2m) | (2.9m) |

CNY | Y, 2019 |
---|---|

## EV/CFO | -5 x |

## Financial Leverage | -2.3 x |

Molecular Data's New Customers was reported to be 16.6 k in Q3, 2019. Molecular Data's Customers was reported to be 110.9 k in Q3, 2019.